

C1
proliferation and/or differentiation and may be employed to treat and/or prevent restenosis and inflammation.--

At Page 33, please replace the paragraph beginning line 14 with the following rewritten paragraph:

Human cytokine polypeptide polynucleotides and polypeptides may be used in accordance with the present invention for a variety of applications, particularly those that make use of the chemical and biological properties of human cytokine polypeptide. Among these are applications in cell proliferation and differentiation. Additional applications relate to diagnosis and to treatment of disorders of cells, tissues and organisms. These aspects of the invention are illustrated further by the following discussion.--

C2
At Page 37, please replace the paragraph beginning line 7 with the following rewritten paragraph:

--The present invention also relates to diagnostic assays such as quantitative and diagnostic assays for detecting levels of human cytokine polypeptide protein in cells and tissues, including determination of normal and abnormal levels. Thus, for instance, a diagnostic assay in accordance with the invention for detecting overexpression of human cytokine polypeptide protein compared to normal control tissue samples may be used to detect the presence of neoplasia, for example. Assay techniques that can be used to determine levels of a protein, such as human cytokine polypeptide protein of the present invention, in a sample

derived from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays. Among these ELISAs frequently are preferred. An ELISA assay initially comprises preparing an antibody specific to human cytokine polypeptide, preferably a monoclonal antibody. In addition a reporter antibody generally is prepared which binds to the monoclonal antibody. To the reporter antibody is attached a detectable reagent such as a radioactive, fluorescent or enzymatic reagent, in this example horseradish peroxidase enzyme. --

C3

In the claims:

Please cancel claims 17-19, 23, and 24 without prejudice.

Remarks

Claims 17-19, 23 and 24 have been cancelled. Claims 25-79 are pending in this application. The specification has been amended to correct typographical errors. No new matter has been added by amendment.

I. Rejections under 35 U.S.C. §§ 101 and 112, First Paragraph

The Examiner rejected claims 25-79 under 35 U.S.C. § 101 as allegedly not being "supported by either a specific and substantial asserted utility or a well-established utility." In particular, the Examiner alleges that "[t]he instant application does not disclose the biological role of this protein or its significance." See, Paper No. 10, Pages 3-4.

Applicants respectfully disagree and traverse this rejection.